Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity

Journal of Immunology

Volumn 167, Issue 11, 2001, Pages 6497-6502

  Kemp, R A ^a   Ronchese, F ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELL MIGRATION; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IN VITRO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0035575704     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.11.6497     Document Type: Article

References (42)

1. Cytokine-secreting tumor cell vaccines
2. Paracrine cytokine adjuvants in cancer immunotherapy
3. - T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
4. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors: Lessons from normal and immunodeficient mice
5. + tumour-infiltrating lymphocytes
6. A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes
7. Interleukin 7 promotes long-term in vitro growth of antitumour cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo
8. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
9. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigens in vivo
10. Induction of antitumour immunity using bone marrow-generated dendritic cells
11. Therapy of murine tumors with tumour peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines
12. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
13. + tumor-infiltrating lymphocytes in human solid tumors
14. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
15. CD4 T cells and their role in antitumor immune responses
16. + T cells in the antitumour immune response
17. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles
18. - cells that make Th2 cytokines and help B cells
19. + T cells secreting Th1 or Th2 cytokines
20. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
21. Disruption of the murine IL-4 gene blocks Th2 cytokine responses
22. + B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses
23. Multiple defects of immune cell function in mice with disrupted interferon-γ genes
24. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge
25. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors
26. The JAM test: A simple assay for DNA fragmentation and cell death
27. Blockade of CD28/B7 co-stimulation by mCTLA4-Hγ1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung
28. Bone marrow-generated dendritic cells pulsed with a class 1-restricted peptide are potent inducers of cytotoxic T lymphocytes
29. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
30. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection
31. + T cell memory by short-term exposure during T cell receptor stimulation
32. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer
33. Murine interleukin-4 displays potent anti-tumor activity in vivo
34. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor
35. An eosinophil-dependent mechanism for the antitumour effect of interleukin-4
36. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
37. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
38. Tumor-selective cytotoxic effects of murine tumor necrosis factor (TNF) and interferon-γ (IFN-γ) in organ culture of B16 melanoma cells and heart tissue
39. IL-10 inhibits cytokine production by activated macrophages
40. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling
41. Functional diversity of helper T lymphocytes
42. + T cell responses: The alternative approaches